American Academy of Ophthalmology Meeting
American Academy of Ophthalmology Meeting
Source/Disclosures
Source:

Regillo CD. Intravitreal gene therapy with ADVM-022 for neovascular AMD: OPTIC phase 1 study. Presented at: American Academy of Ophthalmology annual meeting; Nov. 13-15, 2020 (virtual meeting).

Disclosures: Regillo reports he receives grant support from Genentech, Regeneron, Novartis, Allergan, Astellas, Notal, Chengdu Kanghong, Opthea, Iveric, Adverum, Regenxbio, Kodiak and Graybug and is a consultant with Genentech, Novartis, Allergan, Notal, Takeda, Kodiak, Graybug, Lineage, Opthea, Eyepoint, Iveric, Aldeyra, Merck, Adverum and Chengdu Kanghong.
November 23, 2020
1 min read
Save

Fewer anti-VEGF injections needed after treatment with ADVM-022 in wet AMD

Source/Disclosures
Source:

Regillo CD. Intravitreal gene therapy with ADVM-022 for neovascular AMD: OPTIC phase 1 study. Presented at: American Academy of Ophthalmology annual meeting; Nov. 13-15, 2020 (virtual meeting).

Disclosures: Regillo reports he receives grant support from Genentech, Regeneron, Novartis, Allergan, Astellas, Notal, Chengdu Kanghong, Opthea, Iveric, Adverum, Regenxbio, Kodiak and Graybug and is a consultant with Genentech, Novartis, Allergan, Notal, Takeda, Kodiak, Graybug, Lineage, Opthea, Eyepoint, Iveric, Aldeyra, Merck, Adverum and Chengdu Kanghong.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients with neovascular age-related macular degeneration treated with ADVM-022 in the OPTIC phase 1 study have experienced a substantial reduction in annualized anti-VEGF injection frequency, according to a speaker.

“ADVM-022 is demonstrating a robust treatment response, long-term durability beyond 15 months from a single intravitreal injection and zero rescues in cohort 1, the high-dose cohort,” Carl D. Regillo, MD, FACS, said at the virtual American Academy of Ophthalmology annual meeting.

Regillo presented available data from the four cohorts in the OPTIC phase 1 study, a multicenter, open-label, dose-ranging trial assessing the safety and tolerability of a single intravitreal injection of ADVM-22 (Adverum Biotechnologies). The gene therapy candidate uses a vector capsid to deliver sustained therapeutic levels of Eylea (aflibercept, Regeneron).

Patients in cohort 1 and 4 were treated with a higher dose of ADVM-022 (6 × 1011 vg per eye) compared with cohorts 2 and 3, treated with a threefold lower dose (2 × 1011 vg per eye). Cohorts 1 and 2 included six participants each compared with nine participants in cohorts 3 and 4, Regillo said. Cohorts 1 and 2 underwent a 13-day oral course of steroids, and cohorts 3 and 4 underwent a 6-week prophylactic steroid eye drop regimen.

Before entering the trial, the participants received frequent aflibercept injections to maintain vision. Participants in cohort 1 received zero rescue injections out to 15 months, three participants in cohort 2 required one or more rescue injections by week 48, and two participants in cohort 3 have received additional injections. Rescue and efficacy data were not presented for cohort 4 due to its short follow-up, he said.

“There was good retention of vision in cohort 1 out to 72 weeks with no rescue treatments. Similar in cohort 2 was the same pattern of consistent maintenance of vision, with all patients now beyond 52 weeks. In cohort 3, with a median follow-up of 36 weeks, mean BCVA and [central subfield thickness] were stable and consistent with cohorts 1 and 2. Here, seven of nine patients remained rescue-free,” Regillo said.

The therapy has demonstrated a substantial dose-dependent reduction in annualized injection frequency and a favorable safety profile across all four cohorts with relatively low-grade inflammation well controlled with topical steroids, he said.